Arkolith/Insider Trading/RARE/Form 4

Huizenga Theodore Alan

SVP, Chief Accounting OfficerUltragenyx Pharmaceutical Inc. (RARE) · full profile →Form 4 · filed Sep 19, 2025
Net Selling
Open-Market Buys
$0
Open-Market Sells
$2K
Net Open-Market Flow
-$2K
Transactions
1
1 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Sep 18, 2025Sell(S)64$29.17$2K50K

Transaction Codes

S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001193125-25-209387) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML